GlassScriptPhysician profile
Surabhi Batra
NPI 1972733160
$1,207.52
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.46 · 2020: $13.32 · 2021: $389 · 2022: $39.79 · 2023: $133 · 2024: $336 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $64.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.62 |
| Education | $64.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $375.00 | 2021 | |
| Pfizer INC. | $232.69 | 2023-2024 | |
| Sobi, INC | $124.63 | 2025 | |
| Servier Pharmaceuticals LLC | $76.73 | 2021-2025 | |
| Emmaus Medical, INC. | $68.49 | 2022-2024 | Endari |
| Pharming Healthcare, INC. | $64.00 | 2023 | |
| Azurity Pharmaceuticals, INC. | $52.02 | 2024-2025 | Xatmep, Katerzia |
| Agios Pharmaceuticals, INC. | $46.28 | 2024-2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $36.32 | 2025 | Gomekli |
| Amgen INC. | $27.46 | 2019 | |
| Rare Disease Therapeutics, INC. | $24.28 | 2024 | Purixan |
| Astellas Pharma US INC | $23.97 | 2025 | Cresemba |
| Medunik USA INC. | $22.15 | 2025 | Siklos |
| Adaptive Biotechnologies Corporation | $20.18 | 2024 | Clonoseq |
| Argon Medical Devices, INC. | $13.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.